Not a good buy right now: the broader trend remains bearish (SMA_200 > SMA_20 > SMA_5) and there are no Intellectia entry signals to override that.
Pre-market price (~1.05) is sitting right on S1 support (1.051). That can create a short bounce, but it’s not a high-conviction entry for an impatient buyer because a clean breakdown opens room toward S2 (0.902).
Fundamentals recently deteriorated sharply (revenue collapse in 2025/Q3), and there are no recent news catalysts to change the narrative.
Momentum: MACD histogram is above 0 (0.0105) but positively contracting—suggests a weakening bullish impulse rather than a strong reversal.
RSI: RSI_6 at 27.46 indicates oversold/near-oversold conditions; this can support a reflex bounce, but by itself is not a trend-change confirmation.
Key levels: Support S1 = 1.051 (price ~1.05 is testing it), next support S2 = 0.902. Resistance levels: Pivot 1.291, then R1 1.532.
Near-term pattern stats: Similar-pattern study suggests only modest upside expectations (about +1.62% next day / +0.75% next week / +3.11% next month with ~50% chance), which is not compelling given the downtrend.
Positive Catalysts
and price sitting on S1 support (1.
can produce a short-term technical bounce.
Neutral/Negative Catalysts
Dominant downtrend remains intact (bearish moving-average stack), increasing risk that support breaks.
No recent news catalysts in the last week to drive a sentiment reset.
Trading trends: Hedge funds neutral; insiders neutral—no supportive accumulation signal from major cohorts.
If 1.051 fails decisively, technical room opens toward 0.902 (S2).
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 15,606, down -96.34% YoY (major contraction and the biggest fundamental red flag in the snapshot).
Net income: -4,554,336 (still a sizable loss), improved 16.71% YoY mainly from a loss narrowing perspective.
EPS: -2.02, down -51.09% YoY (worsened per-share performance).
Gross margin: 20 (flat YoY), but margin stability doesn’t offset the sharp revenue drop.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided, so there is no observable recent Wall Street trend to lean on.
Pros view (inferred from available data): limited—no clear positive revisions/catalysts shown.
Cons view (inferred): severe revenue decline and ongoing losses likely keep institutional/coverage enthusiasm muted.
Wall Street analysts forecast HCWB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCWB is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast HCWB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HCWB is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.990
Low
8
Averages
8
High
8
Current: 0.990
Low
8
Averages
8
High
8
Maxim
Buy
downgrade
$120 -> $35
AI Analysis
2025-05-29
Reason
Maxim
Price Target
$120 -> $35
AI Analysis
2025-05-29
downgrade
Buy
Reason
Maxim lowered the firm's price target on HCW Biologics to $35 from $120 but keeps a Buy rating on the shares. The firm cites the company's Q1 results and equity raise in adjusting its price target but also notes that HCW has made considerable progress in shoring up its balance sheet and advancing its pipeline following a challenging legal issue and arbitration, the analyst tells investors in a research note. The company should now have the capital to advance its pipeline and drive a turnaround in share value, Maxim added.
